Table 2.
Summary of immunophenotypic features and MYC rearrangement status
| Total N (%) | PBL-HIV N (%) | PBL-PT N (%) | PBL-AD N (%) | PBL-IC N (%) | |
|---|---|---|---|---|---|
| CD10 | 13/32 (41) | 6/14 (43) | 1/2 (50) | 1/2 (50) | 3/10 (30) |
| CD20 | 0/60 | 0/20 | 0/3 | 0/4 | 0/23 |
| CD45 | 20/40 (50) | 6/11 (54) | 0/1 | 0/2 | 7/18 (39) |
| CD56 | 12/37 (32) | 4/11 (36) | 0/3 | 1/3 (33) | 5/15 (33) |
| CD79a | 13/35 (37) | 2/11 (18) | 0/1 | 1/3 (33) | 6/13 (46) |
| CD138 | 54/58 (93) | 15/19 | 3/3 (100) | 4/4 (100) | 22/23 (96) |
| MUM1 | 22/24 (92) | 8/8 (100) | 2/2 (100) | 3/4 (75) | 7/8 (88) |
| MYC | 13/13 (100) | 7/7 (100) | 1/1 (100) | 0/0 (0) | 4/4 (100) |
| Ki-67 (% median) | 90 | 87.5 | 97.5 | 90 | 80 |
| EBER (ISH) | 40/57 (70) | 19/19 (100)* | 1/3 (33) | 2/4 (50) | 12/22 (55) |
| MYC rearrangement (FISH) | 10/15 (67) | 5/7 (71)** | 1/1 (100) | NA | 3/6 (50) |
PBL plasmablastic lymphoma, HIV human immunodeficiency virus, PT post-transplant, AD autoimmune disease, IC immunocompetent, EBER Epstein- Barr virus-encoded RNA, ISH in situ hybridization; FISH fluorescence in situ hybridization, NA not available
*p = <0.001 (PBL-HIV vs. others); **p = 0.323 (PBL-HIV vs. others)